Richard R. Furman, MD

Richard R. Furman, MD, discusses current treatment options in chronic lymphocytic leukemia.

Richard R. Furman, MD, and Nitin Jain, MD, share insight on the evolving treatment landscape of CLL, particularly for treatment in early line settings.

Nitin Jain, MD, and Richard R. Furman, MD, discuss the standard treatment criteria for CLL and answer audience questions on the appropriate circumstances to adjust, switch, and discontinue therapy.

Nitin Jain, MD, comments on the use of novel treatment strategies, including CAR T-cell therapy, being evaluated to treat patients with CLL.

Nitin Jain, MD, shares factors to consider when selecting the optimal therapy for patients with CLL.

Nitin Jain, MD, provides insight on approaching treatment with noncovalent BTK inhibitors for patients with CLL who have acquired resistance to covalent inhibitors.

Richard R. Furman, MD, reviews resistance mechanisms to BTK inhibitors and how they affect treatment selection for patients with CLL.

Nitin Jain, MD, leads the discussion on the use of fixed-dose regimens for the treatment of CLL as seen in the phase 2 CAPTIVATE and phase 3 GLOW trials.

Richard R. Furman, MD, leads the discussion on clinical implications from head-to-head trials of BTK inhibitors in the relapsed setting for patients with CLL.

Nitin Jain, MD, and Richard R. Furman, MD, review available treatment options for the treatment of CLL and discuss the safety and tolerability of these therapies.

Richard R. Furman, MD, discusses FDA-approved BTK inhibitors in B-cell malignancies.

Richard R. Furman, MD, discusses the safety of acalabrutinib as a monotherapy in hematologic malignancies.

Richard R. Furman, MD, discusses differences among the different available BTK inhibitors for use in patients with B-cell malignancies.

Richard R. Furman, MD, discusses acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia.

Richard R. Furman, MD, discusses the use of BTK inhibitors in chronic lymphocytic leukemia.

Richard R. Furman, MD, discusses the role of prognostic markers in high-risk chronic lymphocytic leukemia.

Over the past few years, remarkable advances have been achieved in the field of chronic lymphocytic leukemia by rationally targeting pathways overexpressed and used by the malignant clone for proliferation and survival.

Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the available agents that have shown promise for patients with chronic lymphocytic leukemia (CLL).

Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses factors to consider when choosing upfront therapy for patients with chronic lymphocytic leukemia (CLL).

Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses second-generation BTK inhibitors, such as acalabrutinib and BGB-3111 in chronic lymphocytic leukemia (CLL).

Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the use of prognostic markers in the treatment of patients with chronic lymphocytic leukemia (CLL).

Richard R. Furman, MD, from the New York Weill Cornell Medical Center, discusses the ability to avoid the administration of chemotherapy when using novel agents, such as idelalisib, to treat patients with chronic lymphocytic leukemia.

Richard R. Furman, MD, from the Weill Cornell Medical Center, discusses the safety profile of the oral BTK inhibitor ibrutinib in both relapsed/refractory and treatment naive patients with chronic lymphocytic leukemia.